Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1996 Dec;75(6):498–501. doi: 10.1136/adc.75.6.498

Relationship between disease severity and inflammatory markers in cystic fibrosis.

D Y Koller 1, M Götz 1, C Wojnarowski 1, I Eichler 1
PMCID: PMC1511810  PMID: 9014602

Abstract

To evaluate the clinical use of measuring neutrophil, lymphocyte, and eosinophil activities, serum myeloperoxidase (MPO), soluble interleukin-2 receptors (sIL-2R), and eosinophil cationic protein (ECP) were measured in 98 patients with cystic fibrosis and in 85 healthy children. Serum concentrations of MPO, sIL-2R, and ECP were increased in patients with cystic fibrosis (median 807 micrograms/l, 4452 pg/ml, 48.8 micrograms/l, respectively) compared with the controls (median 319 micrograms/l, 2743 pg/ml, 9.4 micrograms/l). ECP concentrations, but not serum MPO or sIL-2R, were significantly related to disease severity assessed by the Shwachman-Kulczycki score and by pulmonary function (forced expiratory volume in one second % predicted). Neither ECP nor sIL-2R was influenced by Pseudomonas aeruginosa infection, acute pulmonary exacerbation, or atopy. Serum MPO, however, was strongly correlated with acute pulmonary exacerbation. In the light of these findings the measurement of serum ECP might thus be used for clinical monitoring and for assessing disease severity in cystic fibrosis. The measurement of serum MPO and sIL-2R did not correlate with the disease severity.

Full text

PDF
498

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dagli E., Warner J. A., Besley C. R., Warner J. O. Raised serum soluble interleukin-2 receptor concentrations in cystic fibrosis patients with and without evidence of lung disease. Arch Dis Child. 1992 Apr;67(4):479–481. doi: 10.1136/adc.67.4.479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Eigen H., Rosenstein B. J., FitzSimmons S., Schidlow D. V. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr. 1995 Apr;126(4):515–523. doi: 10.1016/s0022-3476(95)70343-8. [DOI] [PubMed] [Google Scholar]
  3. Flavahan N. A., Slifman N. R., Gleich G. J., Vanhoutte P. M. Human eosinophil major basic protein causes hyperreactivity of respiratory smooth muscle. Role of the epithelium. Am Rev Respir Dis. 1988 Sep;138(3):685–688. doi: 10.1164/ajrccm/138.3.685. [DOI] [PubMed] [Google Scholar]
  4. Koller D. Y., Götz M. Clinical relevance of raised soluble serum interleukin-2 receptor concentrations in cystic fibrosis. Arch Dis Child. 1993 Jan;68(1):150–150. doi: 10.1136/adc.68.1.150-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Koller D. Y., Götz M., Eichler I., Urbanek R. Eosinophilic activation in cystic fibrosis. Thorax. 1994 May;49(5):496–499. doi: 10.1136/thx.49.5.496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Koller D. Y., Urbanek R., Götz M. Increased degranulation of eosinophil and neutrophil granulocytes in cystic fibrosis. Am J Respir Crit Care Med. 1995 Aug;152(2):629–633. doi: 10.1164/ajrccm.152.2.7633718. [DOI] [PubMed] [Google Scholar]
  7. Konstan M. W., Byard P. J., Hoppel C. L., Davis P. B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995 Mar 30;332(13):848–854. doi: 10.1056/NEJM199503303321303. [DOI] [PubMed] [Google Scholar]
  8. Mohammed J. R., Mohammed B. S., Pawluk L. J., Bucci D. M., Baker N. R., Davis W. B. Purification and cytotoxic potential of myeloperoxidase in cystic fibrosis sputum. J Lab Clin Med. 1988 Dec;112(6):711–720. [PubMed] [Google Scholar]
  9. Olofsson T., Olsson I., Venge P., Elgefors B. Serum myeloperoxidase and lactoferrin in neutropenia. Scand J Haematol. 1977 Jan;18(1):73–80. doi: 10.1111/j.1600-0609.1977.tb01480.x. [DOI] [PubMed] [Google Scholar]
  10. Peterson C. G., Enander I., Nystrand J., Anderson A. S., Nilsson L., Venge P. Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo. Clin Exp Allergy. 1991 Sep;21(5):561–567. doi: 10.1111/j.1365-2222.1991.tb00847.x. [DOI] [PubMed] [Google Scholar]
  11. Regnis J. A., Robinson M., Bailey D. L., Cook P., Hooper P., Chan H. K., Gonda I., Bautovich G., Bye P. T. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med. 1994 Jul;150(1):66–71. doi: 10.1164/ajrccm.150.1.8025774. [DOI] [PubMed] [Google Scholar]
  12. SHWACHMAN H., KULCZYCKI L. L. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. AMA J Dis Child. 1958 Jul;96(1):6–15. doi: 10.1001/archpedi.1958.02060060008002. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES